ReviewMaterials (Basel, Switzerland)2021
Recent Advancements in Nanoparticle-Based Optical Biosensors for Circulating Cancer Biomarkers.
Review in Materials (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Breaking barriers in cancer diagnosis: unveiling the 4Ms of biosensors.RSC advances · 2025Review
- Up-Conversion Emissions from HfOACS omega · 2024Article
- Increasing the sensitivity and accuracy of detecting exosomes as biomarkers for cancer monitoring using optical nanobiosensors.Cancer cell international · 2024Review
- Continuous and Non-Invasive Lactate Monitoring Techniques in Critical Care Patients.Biosensors · 2024Review
- Optical nanomaterial-based detection of biomarkers in liquid biopsy.Journal of hematology & oncology · 2024Review
- Advances and prospects of precision nanomedicine in personalized tumor theranostics.Frontiers in cell and developmental biology · 2024Review
- Upregulation of miR-194-5p or silencing of PRC1 enhances radiotherapy sensitivity in esophageal squamous carcinoma cells.Heliyon · 2023Article
- Recent Trends in Lateral Flow Immunoassays with Optical Nanoparticles.International journal of molecular sciences · 2023Review
- Molecular Diagnosis and Cancer Prognosis-A Concise Review.Diagnostics (Basel, Switzerland) · 2023Review
- The recent advancements in the early detection of cancer biomarkers by DNAzyme-assisted aptasensors.Journal of nanobiotechnology · 2022Review
- Quantum Dots for Cancer-Related miRNA Monitoring.ACS sensors · 2022Review
- Novel Detection Method for Circulating EGFR Tumor DNA Using Gravitationally Condensed Gold Nanoparticles and Catalytic Walker DNA.Materials (Basel, Switzerland) · 2022Article
- Carbon Based Nanodots in Early Diagnosis of Cancer.Frontiers in chemistry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The effectiveness of cancer treatment strongly depends on the early detection of the disease. Currently, the most common diagnostic method, tissue biopsy, takes time and can be damaging to the patient. Circulating cancer biomarkers such as circulating tumor DNA, micro-RNA (miRNA), tumor proteins, exosomes, and circulating tumor cells have repeatedly demonstrated their viability as targets for minimally invasive cancer detection through liquid biopsies. However, among other things, achieving a great sensitivity of detection is still challenging due to the very low concentration of biomarkers in fluid samples. This review will discuss how the recent advances in nanoparticle-based biosensors are overcoming these practical difficulties. This report will be focusing mainly on optical transduction mechanisms of metal nanoparticles (M-NPs), quantum dots (QDs), and upconversion nanoparticles (UCNPs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.